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6: When VT is not tolerated, a combination of scar and
pace mapping can be used to identify ablation sites. 
7: The rate of procedure-related death is reported to be 0-
3%, with the most common cause of death being
uncontrolled VT. 
8: The most common complications are stroke, cardiac tam-
ponade, valve injury, and atrioventricular block. 
9: The rate of recurrent VT post-ablation is reported to be
25-50%.
10: There is no evidence that catheter ablation of VT
improves survival.
Summary written by: Fred Morady, MD
2012 HRS/EHRA/ECAS Expert Consensus Statement
on Catheter and Surgical Ablation of Atrial
Fibrillation: Recommendations for Patient
Selection, Procedural Techniques, Patient
Management and Follow-up, Definitions,
Endpoints, and Research Trial Design: A Report of
the Heart Rhythm Society (HRS) Task Force on
Catheter and Surgical Ablation of Atrial Fibrillation
Calkins H, Kuck KH, Cappato R, et al.
Heart Rhythm 2012;Mar 1:[Epub ahead of print].
Perspective: The following are 10 points to remember from this
extensive consensus statement dealing with ablation of atrial
fibrillation (AF): 
1: The only Class I indication for catheter ablation (CA) of
AF is symptomatic paroxysmal AF refractory to ≥1 rhythm-
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Arrhythmias
Catheter Ablation of Ventricular Tachycardia in
Ischaemic and Non-Ischaemic Cardiomyopathy:
Where Are We Today? A Clinical Review
Wissner E, Stevenson WG, Kuck KH.
Eur Heart J 2012;Mar 11:[Epub ahead of print].
Perspective: The following are 10 points to remember from this
review of catheter ablation of ventricular tachycardia (VT) in
patients with structural heart disease (SHD): 
1: Most patients with SHD and monomorphic VT have
ventricular scar caused by prior infarction in patients with
ischemic cardiomyopathy (ICM) or fibrosis in patients with
nonischemic cardiomyopathy (NICM). 
2: Because nonclinical VTs often are inducible in patients
with VT, a 12-lead electrocardiogram of the spontaneous
VT is helpful for identifying clinical VTs in the electrophys-
iology laboratory. 
3: In patients with an implantable cardioverter-defibrillator,
the morphology of the stored electrograms of an episode of
VT can be a useful template for recognizing clinical VTs in
the electrophysiology laboratory. 
4: Epicardial ablation is more likely to be necessary in patients
with NICM and arrhythmogenic right ventricular cardiomy-
opathy/dysplasia than in patients with ICM. 
5: Activation and entrainment mapping are useful for identi-
fying critical sites for ablation of VTs that are
hemodynamically tolerated. 
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of ROSC before hospitalization, but a lower 1-month rate
of survival without severe cerebral dysfunction. 
Perspective: By redirecting peripheral blood flow, epinephrine
increases coronary and cerebral perfusion. This could explain
why epinephrine improved the probability of ROSC before
hospitalization in this study. The reasons that epinephrine
compromises 1-month survival could include increased
myocardial dysfunction, impaired cerebral microcirculation,
and/or an increased risk of ventricular tachycardia/ventricular
fibrillation after resuscitation.
Summary written by:  Fred Morady, MD
Cardiac Biomarkers Are Associated With an
Increased Risk of Stroke and Death in Patients
With Atrial Fibrillation: A RELY Substudy
Hijazi Z, Oldgren J, Andersson U, et al.
Circulation 2012;Feb 28:[Epub ahead of print].
Study Question: Are plasma levels of troponin I and N-terminal
pro-B-type natriuretic peptide (NT-proBNP) predictive of
stroke and vascular mortality in patients with atrial fibrillation?
Methods: Biomarkers were analyzed in 6,189 patients at ran-
domization in the RELY study. Outcomes were evaluated
after adjusting for established cardiovascular risk factors and
the CHADS2 and CHA2DS2-VASc risk scores. Patients
were stratified based on troponin I concentration quartiles:
<0.010; 0.010-0.019; 0.020-0.039; ≥0.040 μg/L; and on
NT-proBNP concentration quartiles: <387; 387-800; 801-
1402; >1402 ng/L. 
Results: Rates of stroke were independently related to levels
of troponin I with 2.09%/year in the highest and 0.84%/year
in the lowest troponin I group (hazard ratio [HR], 1.99),
and to NT-proBNP with 2.30%/year versus 0.92% in the
highest versus lowest NT-proBNP quartile groups (HR,
2.40). Vascular mortality was also independently related to
biomarker levels with 6.56%/year in the highest and
1.04%/year the lowest troponin I group (HR, 4.38), and
5.00%/year in the highest and 0.61%/year in the lowest NT-
proBNP quartile groups (HR, 6.73). Biomarkers increased
the C-statistic from 0.68 to 0.72, p < 0.0001, for a compos-
ite of thromboembolic events. 
Conclusions: Elevations of troponin I and NT-proBNP are
common in patients with atrial fibrillation and are independ-
ently related to increased risks of stroke and mortality.
Perspective: The finding that these biomarkers also predict
stroke in the setting of atrial fibrillation is novel and important
since they improve risk stratification when added to commonly
used clinical scoring methods. This may have important impli-
cations in guiding antithrombotic and other therapies,
especially in atrial fibrillation subgroups otherwise deemed low
risk. Since all patients in this study had at least one stroke risk
1576 Eagle, Cannon
Scanning the Literature
JACC Vol. 59, No. 18, 2012
May 1, 2012:1575-82
control medication.
2: Symptomatic persistent AF refractory to ≥1 rhythm-con-
trol medication is a Class IIa indication for CA.
3: Symptomatic longstanding persistent AF refractory to ≥1
rhythm-control medication is a Class IIb indication for CA. 
4: Symptomatic paroxysmal AF prior to drug therapy is a
Class IIa indication for CA. 
5: Symptomatic persistent and longstanding persistent AF
are Class IIb indications for CA.
6: Symptomatic paroxysmal, persistent, and longstanding
persistent AF are Class IIa indications for concomitant sur-
gical ablation (SA) in patients undergoing surgery for
another indication. 
7: Symptomatic paroxysmal and persistent AF prior to drug
therapy are Class IIa indications for concomitant SA.  
8: Longstanding persistent AF prior to drug therapy is a Class
IIb indication for concomitant SA.
9: All types of symptomatic AF refractory to drug therapy
are Class IIb indications for stand-alone SA, regardless of
whether CA was previously attempted.
10: Stand-alone SA is not recommended for paroxysmal, per-
sistent, or longstanding persistent AF prior to drug therapy.
Summary written by:  Fred Morady, MD
Prehospital Epinephrine Use and Survival Among
Patients With Out-of-Hospital Cardiac Arrest
Hagihara A, Hasegawa M, Abe T, Nagata T, Wakata Y, Miyazaki S.
JAMA 2012;307:1161-1168.
Study Question: Does the use of epinephrine during cardiopul-
monary resuscitation (CPR) affect outcomes in patients with
out-of-hospital cardiac arrest (OHCA)?
Methods: The data for this observational study were obtained
from a registry of 417,188 patients (mean age 72 years) with
OHCA. Epinephrine was administered during CPR in
15,030 patients and not administered in the remaining
402,158 patients. A propensity score for epinephrine
administration was used to control for potential confound-
ing variables. 
Results: Return of spontaneous circulation (ROSC) before
hospitalization occurred significantly more often in the epi-
nephrine group (18.3%) than in the propensity-matched
nonepinephrine group (10.5%). One-month survival with-
out severe cerebral dysfunction was significantly lower in the
epinephrine (1.3%) than the nonepinephrine group (3.1%). 
Conclusions: Administration of epinephrine during CPR in
patients with OHCA is associated with a higher probability
General Cardiology
Incidence and Prognosis of Resistant Hypertension
in Hypertensive Patients
Daugherty SL, Powers JD, Magid DJ, et al.
Circulation 2012;Feb 29:[Epub ahead of print].
Study Question: What is the incidence and importance of resist-
ant hypertension in new-onset hypertension? 
Methods: A retrospective cohort study was conducted in two
integrated health plans that included patients with incident
hypertension started on treatment from 2002-2006. Patients
were followed for the development of resistant hypertension
based on American Heart Association criteria of uncon-
trolled blood pressure (BP) (defined by Joint National
Committee [JNC]-7 thresholds of systolic BP ≥140 mm Hg
or diastolic BP ≥90 mm Hg with lower cut-offs for those
with diabetes or chronic kidney disease) despite use of three
or more antihypertensive medications using medication fill
and BP measurement data. Primary outcome was incident
cardiovascular events (CVEs = death or incident myocardial
infarction, heart failure, stroke, or chronic kidney disease) in
patients with and without resistant hypertension adjusting
for patient and clinical characteristics. 
Results: Among 205,750 patients with incident hypertension,
21% were on three or more antihypertensive medications for
at least 1 month. 1.9% developed resistant hypertension
within a median 1.5 years from initial treatment, or 0.7
cases per 100 person-years of follow-up. Variables associated
with resistant hypertension included men, older, higher
baseline BP, diabetes, chronic kidney disease, and previous
stroke and heart failure. Over 3.8 years of median follow-up,
CVEs were significantly higher in those with resistant
hypertension (unadjusted: 18.0% vs. 13.5%, p < 0.001).
After adjusting for patient and clinical characteristics, resist-
ant hypertension was associated with a higher risk of CVEs
(hazard ratio, 1.47; 95% confidence interval, 1.33-1.62).  
Conclusions: Among patients with incident hypertension
started on treatment, 1 in 50 patients developed resistant
hypertension. Resistant hypertension patients had an in-
creased risk of CVEs, supporting the need for greater efforts
toward improving hypertension outcomes in this population. 
Perspective: Resistant hypertension in this large cohort study is
likely overestimated considering that the BPs were office-
rather than home-based or 24-hour ambulatory. Also, the
definition based on the JNC-7 criteria may be considered too
rigid by some. Nevertheless, the 50% increase in CVEs in
patients with resistant hypertension despite four drugs,
strongly supports a focus on diet and exercise, which have
been shown to reduce BP and reduce CVEs and mortality.
Summary written by: Melvyn Rubenfire, MD
factor and were treated with oral anticoagulants, this approach
will need to be tested in other atrial fibrillation populations.
Summary written by: Daniel T. Eitzman, MD
Congenital Heart Disease
Functional Health Status in Adult Survivors of
Operative Repair of Tetralogy of Fallot
Hickey EJ, Veldtman G, Bradley TJ, et al.
Am J Cardiol 2012;109:873-880.
Study Question: What is the long-term functional health status
of adults with repaired tetralogy of Fallot?
Methods: A single study of 840 patients was performed at a
single center. A phone interview was performed, and review
of charts and echo reports was performed when possible.
The Short Form-36 (SF-36) was used to assess patient-
reported functional status.  
Results: The median age at follow-up was 29.5 years.
Telephone interview, review of echocardiograms, and SF-36
surveys were performed in 706,339 and 396 patients, respec-
tively. Moderate or greater pulmonary valve insufficiency
occurred in 54%, whereas right ventricular outflow tract
stenosis was present in one third of patients. Cardiac symp-
toms were common, occurring in 45% of patients.
Specifically, palpitations occurred in 27%, dyspnea in 21%,
and chest pain in 17% of patients. Compared with age- and
gender-matched normal controls, subjects with tetralogy of
Fallot had significantly abnormal functional status in all
physical functioning domains of the SF-36. Decreased phys-
ical functioning and echocardiographic abnormalities were
more common in older patients (p < 0.0001). 
Conclusions: Physical limitations are common in adults with
repaired tetralogy of Fallot. Efforts to limit ventricular and
outflow tract obstruction may result in improved late func-
tional status. 
Perspective: The primary concern raised by this study is that
functional status seems to worsen with age out of proportion
to what is seen in the general population. Whether changes in
the early surgical approach (single-stage surgery without initial
systemic to pulmonary shunt and avoidance of right ventricu-
lotomy) will lead to improved long-term outcomes in future
patients is unclear. It is also not known whether a strategy of
earlier pulmonary valve replacement may prevent this progres-
sive decline in functional status.
Summary written by: Timothy B. Cotts, MD
JACC Vol. 59, No. 18, 2012
May 1, 2012:1575-82
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A Randomized Trial of Tenecteplase Versus
Alteplase for Acute Ischemic Stroke
Parsons M, Spratt N, Bivard A, et al.
N Engl J Med 2012;366:1099-1107.
Study Question: What is the comparative efficacy of the stan-
dard dose of alteplase with two different doses of
tenecteplase? 
Methods: In this phase 2B trial, the investigators randomly
assigned 75 patients to receive alteplase (0.9 mg/kg of body
weight) or tenecteplase (0.1 mg/kg or 0.25 mg/kg) less than
6 hours after the onset of ischemic stroke. To favor the
selection of patients most likely to benefit from throm-
bolytic therapy, the eligibility criteria were a perfusion lesion
at least 20% greater than the infarct core on computed
tomographic (CT) perfusion imaging at baseline and an
associated vessel occlusion on CT angiography. The copri-
mary endpoints were the proportion of the perfusion lesion
that was reperfused at 24 hours on perfusion-weighted mag-
netic resonance imaging and the extent of clinical
improvement at 24 hours, as assessed on the National
Institutes of Health Stroke Scale (NIHSS, a 42-point scale;
higher scores indicate more severe neurologic deficits). 
Results: The three treatment groups each comprised 25
patients. The mean NIHSS score at baseline for all patients
was 14.4, and the time to treatment was 2.9 hours.
Together, the two tenecteplase groups had greater reperfu-
sion (p = 0.004) and clinical improvement (p < 0.001) at 24
hours than the alteplase group. There were no significant
between-group differences in intracranial bleeding or other
serious adverse events. The higher dose of tenecteplase (0.25
mg/kg) was superior to the lower dose and to alteplase for
all efficacy outcomes, including absence of serious disability
at 90 days (in 72% of patients, vs. 40% with alteplase; p =
0.02).
Conclusions: Tenecteplase was associated with significantly
better reperfusion and clinical outcomes than alteplase in
patients with stroke. 
Perspective: The current study reports that, using CT perfu-
sion and angiographic imaging to select patients for
thrombolytic treatment of acute ischemic stroke,
tenecteplase was superior to alteplase with respect to reper-
fusion and clinical improvement at 24 hours, and did not
increase intracranial hemorrhage. These positive findings
should be considered preliminary, due to the small sample
size.
Summary written by: Debabrata Mukherjee, MD
Association of Hospital Spending Intensity With
Mortality and Readmission Rates in Ontario
Hospitals
Stukel TA, Fisher ES, Alter DA, et al.
JAMA 2012;307:1037-1045.
Study Question: What is the association between higher spend-
ing in hospitals with mortality and readmissions? 
Methods: The study population was comprised of adults (>18
years) in Ontario, Canada, with a first admission for acute
myocardial infarction (AMI) (n = 179,139), congestive heart
failure (CHF) (n = 92,377), hip fracture (n = 90,046), or
colon cancer (n = 26,195) during 1998-2008, with follow-up
to 1 year. The exposure measure was the index hospital’s
end-of-life expenditure index for hospital, physician, and
emergency department services. The primary outcomes were
30-day and 1-year mortality, and readmissions and major
cardiac events (readmissions for AMI, angina, CHF, or
death) for AMI and CHF.
Results: Patients’ baseline health status was similar across
hospital expenditure groups. Patients admitted to hospitals
in the highest- versus lowest-spending intensity terciles had
lower rates of all adverse outcomes. In the highest- versus
lowest-spending hospitals, respectively, the age- and sex-
adjusted 30-day mortality rate was 12.7% versus 12.8% for
AMI, 10.2% versus 12.4% for CHF, 7.7% versus 9.7% for
hip fracture, and 3.3% versus 3.9% for CHF. Results for 1-
year mortality, readmissions, and major cardiac events were
similar. Higher spending hospitals had higher nursing staff
ratios, and their patients received more inpatient medical
specialist visits, interventional and medical cardiac therapies,
preoperative specialty care, and post-discharge collaborative
care with a cardiologist and primary care physician. 
Conclusions: Among Ontario hospitals, higher spending inten-
sity was associated with lower mortality, readmissions, and
cardiac event rates. 
Perspective: It would be simplistic to interpret this study as sug-
gesting that higher spending is causally related to better
outcomes and that providing more money to lower-spending
hospitals would automatically improve their outcomes. Higher
spending hospitals differed in many ways, such as greater use
of evidence-based care, skilled nursing and critical care staff,
more intensive inpatient specialist services, and high technol-
ogy, all of which are more expensive. It is critical to
understand not only how much money is spent, but whether it
is spent on effective procedures and services.
Summary written by: Debabrata Mukherjee, MD
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ment of incident cardiac complications is independently
associated with a 60% increase in the risk of short-term mor-
tality in patients with CAP. The study findings provide
support for increasing efforts to reduce the incidence of
pneumonia in high-risk populations through influenza and
pneumococcal vaccination.
Summary written by: Debabrata Mukherjee, MD
Effect of a Monoclonal Antibody to PCSK9 on LDL
Cholesterol
Stein EA, Mellis S, Yancopoulos GD, et al.
N Engl J Med 2012;366:1108-1118.
Study Question: What is the effect of proprotein convertase
subtilisin/kexin 9 (PCSK9) inhibition on levels of low-den-
sity lipoprotein (LDL) cholesterol? 
Methods: In healthy volunteers, two randomized studies of an
antibody to PCSK9 (REGN727) given intravenously (40
subjects) or subcutaneously (32 subjects) was compared with
placebo. These studies were followed by a randomized,
placebo-controlled, multiple-dose trial in adults with hetero-
zygous familial hypercholesterolemia who were receiving
atorvastatin (21 subjects) and in nonfamilial hypercholes-
terolemia subjects on atorvastatin (30 subjects) (baseline
LDL >100 mg/dl) or a modified diet alone (10 subjects)
(baseline LDL >130 mg/dl). The primary outcome for all
studies was safety; secondary outcome was the lipid profile. 
Results: Among subjects receiving REGN727, there were no
discontinuations because of adverse events, and REGN727
lowered LDL in all the studies. In a multiple-dose study,
REGN727 doses of 50, 100, and 150 mg reduced LDL lev-
els in the combined atorvastatin-treated populations to 77.5,
61.3, and 53.8 mg/dl, for a difference in the change from
baseline of −39.2, −53.7, and −61.0%, respectively, as com-
pared with placebo (p < 0.001 for all comparisons). 
Conclusions: In three phase 1 trials, REGN727 significantly
reduced LDL cholesterol levels in healthy volunteers and in
subjects with familial or nonfamilial hypercholesterolemia. 
Perspective: The PCSK9 protease is a promising therapeutic
target that when blocked, should lead to reduced LDL and
reduced coronary artery disease risk. This study demonstrates
that a monoclonal antibody to PCSK9 leads to dose-depen-
dent, prolonged reductions in LDL, and this effect is
additive to statins in a diverse hyperlipidemic population.
This therapy may be useful in statin-intolerant patients and
in combination with statins in high-risk populations to
achieve extreme lowering of LDL. The effects of REGN727
on vascular events and the long-term safety profile will
require further study.
Summary written by: Daniel T. Eitzman, MD
Cardiac Complications in Patients With
Community-Acquired Pneumonia: Incidence,
Timing, Risk Factors, and Association With
Short-Term Mortality
Corrales-Medina VF, Musher DM, Wells GA, Chirinos JA, Chen L,
Fine MJ.
Circulation 2012;125:773-781.
Study Question: What are the type, frequency, and timing of
incident cardiac complications; their risk factors; and associ-
ations with short-term mortality in patients with
community-acquired pneumonia (CAP)?
Methods: A total of 1,343 inpatients and 944 outpatients
with CAP were followed up prospectively for 30 days after
presentation. Incident cardiac complications (new or wors-
ening heart failure, new or worsening arrhythmias, or
myocardial infarction) were diagnosed in 358 inpatients
(26.7%) and 20 outpatients (2.1%). For the univariable
analysis of baseline factors and incident cardiac complica-
tions, the authors used unpaired t tests or Wilcoxon
rank-sum tests for continuous variables and χ2 or Fisher
exact tests for categorical variables, as appropriate.
Results: Although most events (89.1% in inpatients, 75% in
outpatients) were diagnosed within the first week, more
than half of them were recognized in the first 24 hours.
Factors associated with their diagnosis included older age
(odds ratio [OR], 1.03; 95% confidence interval [CI], 1.02-
1.04), nursing home residence (OR, 1.8; 95% CI, 1.2-2.9),
history of heart failure (OR, 4.3; 95% CI, 3.0-6.3), prior
cardiac arrhythmias (OR, 1.8; 95% CI, 1.2-2.7), previously
diagnosed coronary artery disease (OR, 1.5; 95% CI, 1.04-
2.0), arterial hypertension (OR, 1.5; 95% CI, 1.1-2.1),
respiratory rate ≥30 breaths per minute (OR, 1.6; 95% CI,
1.1-2.3), blood pH <7.35 (OR, 3.2; 95% CI, 1.8-5.7), blood
urea nitrogen ≥30 mg/dl (OR, 1.5; 95% CI, 1.1-2.2), serum
sodium <130 mmol/L (OR, 1.8; 95% CI, 1.02-3.1), hemat-
ocrit <30% (OR, 2.0; 95% CI, 1.3-3.2), pleural effusion on
presenting chest X-ray (OR, 1.6; 95% CI, 1.1-2.4), and
inpatient care (OR, 4.8; 95% CI, 2.8-8.3). Incident cardiac
complications were associated with increased risk of death at
30 days after adjustment for baseline Pneumonia Severity
Index score (OR, 1.6; 95% CI, 1.04-2.5). 
Conclusions: Incident cardiac complications are common in
patients with CAP and are associated with increased short-
term mortality.
Perspective: This study suggests that incident cardiac compli-
cations occur in a substantial proportion of patients with
CAP, affecting more than one quarter of those hospitalized
for this infection; that the great majority of CAP patients
who develop incident cardiac complications have their pri-
mary cardiac event within 7 days of presentation, with >50%
occurring the same day of CAP diagnosis; and the develop-
JACC Vol. 59, No. 18, 2012
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Decision Making in Advanced Heart Failure:
A Scientific Statement From the
American Heart Association 
Allen LA, Stevenson LW, Grady KL, et al.
Circulation 2012;Mar 5:[Epub ahead of print].
Perspective: The following are 10 points to remember about
this Scientific Statement: 
1: There are complex trade-offs in the management of
patients with several comorbidities that compel clinicians to
come up with an optimal management plan that incorpo-
rates patient goals, values, and preferences. 
2: It is important that the clinician recognizes the natural
history of heart failure in the individual patient, especially
the critical transition into advanced heart failure, because
this is often accompanied by a transition in goals of care
from the patient and family perspective, wherein palliative
therapies may become the dominant treatment paradigm
when transplantation and mechanical circulatory support are
not an option.  
3: Frequent reappraisal of the clinical course helps manage
expectations, improve communication, and inform rational
decisions. A comprehensive discussion of prognosis includes
the potential impact of worsening symptoms, limited func-
tional capacity, loss of independence, reduced social
functioning, decreased quality of life, and increased caregiver
commitment in addition to the risk of death.
4: It is important for the physician to define the range of
options that are medically appropriate. 
5: An annual heart failure review with patients should
include discussion of current and potential therapies for
both anticipated and unanticipated events, as well as
responding to clinical milestones.
6: It is important for the clinician to initiate the develop-
ment of a comprehensive plan for end-of-life care consistent
with patient values, preferences, and goals. ICD deactivation
is desirable to avoid unnecessary pain and distress for
patients and families at the end of life. Active discontinua-
tion of mechanical circulatory support is often appropriate
and necessary at the end of life. 
7: Although family units may have discussed end-of-life
preferences, important barriers to such discussions include
fear of death, trust in others to make decisions, family
dynamics, uncertainty about preferences, and psychological
burdens associated with surrogate decision making.
8: The decision-making process and communication are
described in detail in this statement.
9: The expert panel opined that future research is needed in
a variety of areas related to shared decision making (includ-
ing effective communication training, decision support
interventions, group visits, health-related quality-of-life
measures, and caregiver burden, needs, and outcomes).
10: Changes in organizational and reimbursement structure
will be required to reward and integrate decision making into
the delivery of patient-centered health care.
Summary written by: Ragavendra R. Baliga, MBBS
Impact of Progression of Diastolic Dysfunction on
Mortality in Patients With Normal Ejection Fraction
Aljaroudi W, Alraies MC, Halley C, et al.
Circulation 2012;125:782-788.
Study Question: What is the impact of progression of diastolic
dysfunction (DD) on all-cause mortality in patients initially
evaluated as ambulatory outpatients? 
Methods: Clinical records and echocardiograms of 1,065 con-
secutive patients who underwent a baseline echocardiogram
between January 1, 2005, and December 31, 2009, and who
also had a follow-up echocardiogram within 6-24 months
were reviewed. All-cause mortality was assessed by use of
the Social Security Death Index. Diastolic function was
labeled as normal, mild, moderate, or severe dysfunction
corresponding to normal, and grade 1, 2, and 3 diastolic
function. 
Results: Average patient age was 67.9 years and 58% were
male. Baseline DD was noted in 770 patients (72.3%), and
was mild in 65.9% and moderate or severe in 7.4%. Clinical
association with baseline DD included increasing age and
hypertension. For the whole group, average time between
echocardiograms was 1.1 ± 0.4 years; average follow-up was
1.6 ± 0.8 years. At baseline, all patients had normal left ven-
tricular (LV) systolic function. Diastolic function remained
stable in 783 patients, worsened in 168, and improved in 14.
A decrease in LVEF to <55% was noted in 88 patients of
whom 60 had stable, 19 worsening, and 9 improved diastolic
function. On follow-up, all-cause mortality was reported in
142 patients, including 20 with normal diastolic function,
102 with mild DD, and 20 with at least moderate DD.
Conclusions: In patients with normal baseline LV systolic
function, development of DD or worsening of pre-existing
DD independently predicts all-cause mortality. 
Perspective: This large study nicely demonstrated an inde-
pendent impact of subsequent development of DD on
all-cause mortality in these patients with preserved LV sys-
tolic function. The mechanism by which diastolic function
relates to adverse outcomes probably relates to progression of
underlying disease whether it is ischemic heart disease,
hypertensive cardiovascular disease, or other clinical entities.
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Whether more aggressive therapy in patients noted to have
progression of DD on echocardiography would have an
impact on prognosis remains conjectural.
Summary written by: William F. Armstrong, MD
Interventional Cardiology
Intracoronary Versus Intravenous Bolus Abciximab
During Primary Percutaneous Coronary
Intervention in Patients With Acute ST-Elevation
Myocardial Infarction: A Randomised Trial
Thiele H, Wöhrle J, Hambrecht R, et al.
Lancet 2012;379:923-931.
Study Question: What is the safety and efficacy of intracoro-
nary versus intravenous abciximab in patients undergoing
primary percutaneous coronary intervention (PCI)? 
Methods: AIDA STEMI was a randomized, open-label, mul-
ticenter trial in which patients undergoing primary PCI for
ST-segment elevation myocardial infarction (STEMI) were
randomly assigned in a 1:1 ratio to intracoronary versus
intravenous abciximab bolus (0.25 mg/kg bodyweight) dur-
ing PCI with a subsequent 12-hour intravenous infusion
0.125 μg/kg/min. The primary endpoint was a composite of
all-cause mortality, recurrent infarction, or new congestive
heart failure (CHF) within 90 days of randomization. 
Results: A total of 2,065 patients were randomly assigned to
intracoronary (n = 1,032) or intravenous abciximab (n =
1,033). There was no difference in the primary composite
clinical endpoint at 90 days (7.0% vs. 7.6%; odds ratio,
0.91; 95% confidence interval, 0.64-1.28; p = 0.58). There
was no difference in the incidence of death (4.5% vs. 3.6%;
1.24; 0.78-1.97; p = 0.36) or reinfarction (1.8% vs. 1.8%;
1.0; 0.51-1.96; p = 0.99) between the treatment groups.
New-onset CHF was less commonly seen in the intracoro-
nary group (2.4% vs. 4.1%; 0.57; 0.33-0.97; p = 0.04). 
Conclusions: In patients with STEMI undergoing primary PCI,
intracoronary as compared to intravenous abciximab did not
result in a difference in the combined endpoint of death, rein-
farction, or CHF. 
Perspective: This study did find a reduction in CHF with
intracoronary abciximab, although this may be a chance
finding since there was no difference in ST resolution or
final left ventricular ejection fraction between the two
groups. However, there is no downside to intracoronary
abciximab (over intravenous use), and in the rare circum-
stance when abciximab is used, it may be reasonable to
administer it directly to the infarct vessel.
Summary written by: Hitinder S. Gurm, MBBS
Prevention/Vascular
Comparison of the Framingham and Reynolds Risk
Scores for Global Cardiovascular Risk Prediction in
the Multiethnic Women’s Health Initiative
Cook NR, Paynter NP, Eaton CB, et al.
Circulation 2012;Mar 7:[Epub ahead of print].
Study Question: How does the Reynolds Risk Score compare
with Framingham-based risk scores in the prediction of car-
diovascular disease (CVD) risk?
Methods: A case-cohort sample from the Women’s Health
Initiative (WHI) Observational Cohort was used for the
present study. Incident cases included myocardial infarction
(MI), ischemic stroke, and CVD death. The control group
comprised a random sample of women from the WHI with-
out prior CVD. CVD risk was calculated using the ATP-III
score, Reynolds Risk Score, and Framingham CVD model,
reweighting to reflect cohort frequencies. 
Results: Major CVD cases (n = 1,722) included 752 MIs,
754 ischemic strokes, and 216 CVD deaths. The sample of
controls was comprised of 1,994 without prior CVD. Cases
included more smokers and diabetics, and generally higher
risk factor levels. Blacks were slightly younger than whites,
but had higher proportions of smokers and diabetics. The
predicted 10-year risk varied widely between models, with
10% or higher risk in 6%, 10%, and 41% of women using
the ATP-III, Reynolds, and Framingham CVD models,
respectively. The ATP-III and Framingham CVD models
overestimated risk for CHD and major CVD. After recali-
bration, the Reynolds model demonstrated improved
discrimination over the ATP-III model through a higher c-
statistic (0.765 vs. 0.757), positive net reclassification
improvement (NRI) (4.9%), and positive integrated discrim-
ination improvement (IDI) (4.1%) overall, excluding
diabetics (NRI = 4.2%), and in white (NRI = 4.3%) and
black (NRI = 11.4) women. The Reynolds (NRI = 12.9)
and ATP-III (NRI = 5.9%) models demonstrated better
discrimination than the Framingham CVD model. 
Conclusions: The Reynolds Risk Score was better calibrated
than the Framingham-based models in this large external
validation cohort. The Reynolds score demonstrated
improved discrimination among both black and white
women. 
Perspective: This well written paper suggests that the
Reynolds Risk Score has significant clinical utility for
addressing risk among women, and has significant implica-
tions for management of CVD risk factors.
Summary written by: Elizabeth A. Jackson, MD 
JACC Vol. 59, No. 18, 2012
May 1, 2012:1575-82
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A Randomized Trial of Nicotine-Replacement
Therapy Patches in Pregnancy
Coleman T, Cooper S, Thornton JG, et al., on behalf of the
Smoking, Nicotine, and Pregnancy (SNAP) Trial Team.
N Engl J Med 2012;366:808-818.
Study Question: Are nicotine-replacement therapies safe and
effective for smoking cessation during pregnancy? 
Methods: Participants (16-50 years old) were recruited from
seven hospitals in England between May 2007 and February
2010. All women were between 12 and 24 weeks’ gestation
and had smoked 10 or more cigarettes daily before preg-
nancy, were currently smoking five or more cigarettes per
day, and had an exhaled carbon monoxide concentration of
at least 8 ppm. All participants received behavioral cessation
support and were also randomly assigned to 8 weeks of treat-
ment with active nicotine patches (15 mg per 16 hours) or
matched placebo patches. The primary outcome was absti-
nence from the date of smoking cessation until delivery,
validated by exhaled carbon monoxide measurement. Safety
outcomes included adverse events related to pregnancy and
birth. 
Results: A total of 1,050 women were enrolled, of which 521
were randomly assigned to nicotine replacement therapy and
529 to placebo. No difference was observed in the absti-
nence rate (from quit date to delivery date) between the two
groups (nicotine patch vs. placebo patch) with an unadjusted
odds ratio for the nicotine replacement group of 1.26 for
smoking abstinence. However, during the first month, the
abstinence rate was higher among the nicotine replacement
group compared to placebo (21.3% vs. 11.7%). Compliance
was low for both groups, with 7.2% of women assigned to
the nicotine replacement group and 2.8% of women
assigned to placebo using patches for more than 1 month.
Rates of adverse pregnancy and adverse birth outcomes were
similar between the two groups.
Conclusions: Adding a nicotine patch to behavior support for
smoking cessation during pregnancy did not significantly
increase the rate of abstinence or the risk for adverse events
during pregnancy or with birth. However, low compliance sig-
nificantly limited the assessment of safety. 
Perspective: These data suggest that nicotine replacement
may be safe during pregnancy; however, as the investigators
note, the low compliance limits this finding. Additional
research regarding the factors that are associated with low
compliance for smoking cessation will provide information
on the design of future interventions for women who smoke
during pregnancy.
Summary written by: Elizabeth A. Jackson, MD
The Interleukin-6 Receptor as a Target for
Prevention of Coronary Heart Disease: A Mendelian
Randomisation Analysis
The Interleukin-6 Receptor Mendelian Randomisation Analysis
(IL6R MR) Consortium.
Lancet 2012;Mar 14:[Epub ahead of print].
Study Question: What is the effect of interleukin-6 receptor
(IL6R) signaling on coronary heart disease (CHD)? 
Methods: Single nucleotide polymorphisms (SNPs) in the
IL6R were determined to evaluate the likely efficacy and
safety of IL6R inhibition for primary prevention of CHD.
Genetic findings were compared with the effects of the IL6
antibody, tocilizumab, reported in trials involving patients
with rheumatoid arthritis.
Results: In 133,449 individuals, an IL6R SNP (rs7529229)
marking a nonsynonymous IL6R variant (rs8192284;
p.Asp358Ala) was associated with increased IL6 concentra-
tions (9.45% per allele) as well as reduced C-reactive
protein (decrease 8.35% per allele) and fibrinogen concen-
trations (0.85% decrease per allele). This pattern was
consistent with IL6R blockade from infusions of
tocilizumab in patients with rheumatoid arthritis studied in
randomized trials. In 25,458 CHD cases and 100,740 con-
trols, the IL6R rs7529229 SNP was associated with
reduced odds of CHD events (per allele odds ratio 0.95, p =
1.53 × 10–5). 
Conclusions: IL6R signaling seems to have a causal role in the
development of CHD. 
Perspective: Although associations with IL6 and CHD have
been previously demonstrated, causality between CHD and
IL6R signaling has been unclear. By showing that a func-
tional IL6R gene variant is associated with reduced CHD
risk, this study provides strong support for IL6R as a valid
therapeutic target for the prevention of CHD. Since
tocilizumab is already in use in patients with rheumatoid
arthritis, and leads to similar changes in biomarkers as the
gene variant, one might predict that this drug will have ben-
eficial vascular effects. The safety and magnitude of benefit
of this drug (or other IL6R antagonists) will need to be
tested in further trials.
Summary written by: Daniel T. Eitzman, MD
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